TH-302 - Hypoxia-activated Pro-drug. CAS# 918633-87-1 size:2mg solid a potent inhibitor of the

a potent inhibitor of the epidermal growth factor receptor

Molecular Weight: 432

Human bone marrow derived mesenchymal stem cells from three different donors were treated with Daidzein-2c and shown to exhibit enhanced osteogenesis when compared to daidzein or estrogen treatment

4-dihydro-1

2ClH/c1-22-17-8-7-14(18(12-17)23-2)11-15-5-4-10-21-19(15)16-6-3-9-20-13-16

TH-302 - Hypoxia-activated Pro-drug. CAS# 918633-87-1 size:2mg solid a potent inhibitor of theTH 302, CAS No. 918633 87 1, is a highly potent and selective hypoxia activated pro drug targeting hypoxic regions of solid tumors with an IC50 of 19 nM. It is stable to liver microsomes. However, under hypoxic conditions, it is selectively and irreversibly converted to its active phosphoramidate based, DNA crosslinking, bis alkylator. TH 302 inhibits H460 cells and HT29 cells with IC90 of 0. 1 M and 0. 2 M, respectively. It shows much enhanced